Clinical Trial Update: Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X] [Phase 2, Phase 3]

View source ↗

Summary

Update on safety and efficacy of AMT-011, a gene therapy vector delivering human lipoprotein lipase (LPL S447X), in subjects with familial Lipoprotein Lipase De…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Lipoprotein Lipase Deficiency

Drugs mentioned

• AMT-011 (lipoprotein lipase gene therapy vector expressing human LPL S447X)

Snippet

Sponsor: Amsterdam Molecular Therapeutics | Conditions: Familial Lipoprotein Lipase Deficiency | Phase 2, Phase 3 | Status: UNKNOWN